Follow Us!
What's new
- The Efficacy and Safety of Colistimethate Sodium Delivered Via the I-neb in Patients with Bronchiectasis and Pseudomonas aeruginosa Infection: the PROMIS-I and PROMIS-II Randomized Controlled Trials
- Jan 2025 PINE Webinar Recording
- HIV PINE
- PINE Endemic Fungal Infections
- PITB October 2024 Updated Highlights Newsletter
Featured
Assembly Chair
Kenneth Olivier, MD, MPH, ATSF
Welcome to the website of the Assembly for Pulmonary Infections and Tuberculosis (PI-TB). The PI-TB Assembly represents clinicians, scientists, and public health practitioners from across the globe. Our assembly focuses on all aspects of pulmonary infections and host defense. At present, we have1037 primary members and 2247 secondary members, with almost half of our membership from outside of North America.
We are one of the most productive and visible Assemblies within ATS. Our statements and guidelines are highly cited and have helped to establish and improve practice in the diagnosis and treatment of a wide variety of pulmonary infections, including community-acquired pneumonia, hospital-acquired/ventilator-associated pneumonia, and pneumonia in the immunocompromised host; tuberculosis and nontuberculous mycobacterial infections; fungal infections; and bronchiectasis. Our symposia and mini symposia at the ATS Annual Meeting continue to provide some of the best opportunities for clinicians and scientists to be kept abreast of recent advances in the diagnosis, treatment, and control of respiratory infections. Thematic poster sessions allow interaction with some of the cutting-edge research in these areas.
This is an exciting yet challenging time to be involved with pulmonary infections. Improving diagnostics and advances in development of blood-based assays for identifying and quantifying lung infections, new and re-purposed antibiotics for both mycobacterial and bacterial pneumonia, and emerging data regarding the lung microbiome and its role in pulmonary disease have stimulated great interest. Conversely, the increase in multidrug-resistant (MDR) and extremely drug-resistant (XDR) strains of bacteria and tuberculosis pose a threat to the dramatic improvements in health resulting from effective antibiotics. Pandemic influenza, SARS, MERS and COVID19 have also increased awareness of the role of serious viral respiratory tract infections and of the evolving need for more effective antiviral treatment for both new and previously known respiratory viruses.
So if the challenge of clinical management, understanding pathophysiology and epidemiology, , or developing novel diagnostics and new treatment paradigms for respiratory infections is of interest to you, we encourage you to join us in the PI-TB Assembly. Our Assembly particularly encourages participation by junior members, including fellows and early career members as well as PhD, translational and basic science investigators through a variety of programs in order to meet the future challenges in pulmonary infections. For more information about the Assembly contact us at pitb@thoracic.org.
Kenneth N. Olivier, MD, MPH, ATSF, Assembly Chair
Charles Dela Cruz, MD, PhD, ATSF, Immediate, Past Assembly Chair
Pamela J. Mcshane, MD, Chair, and Kelly M. Pennington, MD, Program Chairs
Kristina Crothers, MD, Planning Chair
Eva Otoupalova, MD and Andrew Roth, MD, Web Directors
